MedImmune is reducing its revenue and earnings guidance for the 2003 fourth quarter and full year as outlined below. Driving these changes is a reduction in expected FluMist revenues for the full year of 2003 to $55 million to $85 million from the previously stated guidance of $120 million to $140 million. As a result, total revenues for 2003 have been reduced to a range of $1.04 billion to $1.1 billion from the previously stated guidance of $1.1 billion to $1.15 billion. Adjusted earnings per diluted share for 2003 are now expected to range from $0.72 to $0.80 versus prior guidance of $0.88 to $0.93. GAAP earnings per diluted share for 2003 are now expected to be $0.68 to $0.76 versus prior guidance of $0.84 to $0.89.
O Clubeinvest.com informa que nenhuma da informação
aqui facultada deverá ser entendida como conselho ou recomendação
de qualquer tipo de transacção ou investimento.
